Presenile dementia syndromes: an update on taxonomy and diagnosis
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Lumacaftor-ivacaftor (Orkambi) was recently approved by the Food and Drug Administration (FDA) in the USA to treat patients at least 12 years old who have cystic fibrosis due to two copies of the F508del (Phe508del) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Lumacaftor-ivacaftor has been designated a ‘breakthrough’ and is slated to cost $259 000 per year per patient, but close scrutiny of the data behind this new medication reveals modest improvements in outcomes that are not exclusively benefited by lumacaftor-ivacaftor, and the $259 000 cost is questionable and problematic. Providers considering this therapy should have a candid and easily-understandable discussion with their patients about what the data show for lumacaftor-ivacaftor so their patients can make an informed decision about taking it. This article aims to help this process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prusiner, S. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13363 · Cited by 5,373
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Staging of alzheimer's disease-related neurofibrillary changes
Braak, H., & Braak, E. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00021-6 · Cited by 2,357
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
SEMANTIC DEMENTIA: PROGRESSIVE FLUENT APHASIA WITH TEMPORAL LOBE ATROPHY
HODGES, J. R., PATTERSON, K., OXBURY, S., & FUNNELL, E. (1992) · Brain · doi:10.1093/brain/115.6.1783 · Cited by 1,710
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
Cited by
Early-Versus Late-Onset Alzheimer's Disease: More than Age Alone
Koedam, E. L. G. E., Lauffer, V., van der Vlies, A. E., van der Flier, W. M., Scheltens, P., & Pijnenburg, Y. A. L. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1337 · Cited by 452
Epidemiology of early-onset dementia: a review of the literature
Vieira, R. T., Caixeta, L., Machado, S., Silva, A. C., Nardi, A. E., Arias-Carrión, O., & Carta, M. G. (2013) · Clinical Practice & Epidemiology in Mental Health · doi:10.2174/1745017901309010088 · Cited by 325
Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele
van der Flier, W. M., Pijnenburg, Y. A., Fox, N. C., & Scheltens, P. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70306-9 · Cited by 306
Does This Patient Have Dementia?
Holsinger, T., Deveau, J., Boustani, M., & Williams, J. W. (2007) · JAMA · doi:10.1001/jama.297.21.2391 · Cited by 305
Precuneus atrophy in early-onset Alzheimer’s disease: a morphometric structural MRI study
Karas, G., Scheltens, P., Rombouts, S., van Schijndel, R., Klein, M., Jones, B., van der Flier, W., Vrenken, H., & Barkhof, F. (2007) · Neuroradiology · doi:10.1007/s00234-007-0269-2 · Cited by 295
Hypocretin (orexin) loss in Alzheimer's disease
Fronczek, R., van Geest, S., Frölich, M., Overeem, S., Roelandse, F. W. C., Lammers, G. J., & Swaab, D. F. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.03.014 · Cited by 254
Hutchinson, A. D., & Mathias, J. L. (2007) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.100669 · Cited by 187
Early onset Alzheimer’s disease is associated with a distinct neuropsychological profile
Smits, L. L., Pijnenburg, Y. A. L., Koedam, E. L. G. E., van der Vlies, A. E., Reuling, I. E. W., Koene, T., Teunissen, C. E., Scheltens, P., & van der Flier, W. M. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111934 · Cited by 182
“Based on the atypical presentation which has formerly been described [2-5] and on the quite common observation of a different distribution of atrophy with prominent involvement of the posterior cortices, [14-16] we hypothesized patients with early onset AD to be more impaired on visuo-spatial functioning and less impa…”
Geschwind, M. D., Haman, A., & Miller, B. L. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.04.001 · Cited by 143
Early onset dementia: clinical and social aspects
Werner, P., Stein-Shvachman, I., & Korczyn, A. D. (2009) · International Psychogeriatrics · doi:10.1017/s1041610209009223 · Cited by 122
“Many diseases and conditions have been identified as causes of EOD, such as Alzheimer’s disease (AD), vascular dementia (VaD), frontotemporal lobar degeneration (FTLD), dementia with Lewy bodies (DLB), cerebral vasculitis, Parkinson’s disease, Huntington’s disease, progressive supranuclear palsy, amyotrophic lateral s…”
BackgroundCSF neurofilament proteins in the differential diagnosis of dementia
de Jong, D., Jansen, R. W. M. M., Pijnenburg, Y. A. L., van Geel, W. J. A., Borm, G. F., Kremer, H. P. H., & Verbeek, M. M. (2007) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.107326 · Cited by 120
Whole-brain atrophy rate in Alzheimer disease: Identifying fast progressors
Sluimer, J. D., Vrenken, H., Blankenstein, M. A., Fox, N. C., Scheltens, P., Barkhof, F., & van der Flier, W. M. (2008) · Neurology · doi:10.1212/01.wnl.0000311446.61861.e3 · Cited by 110
Zhao, Y., Xin, Y., Meng, S., He, Z., & Hu, W. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.04.014 · Cited by 105
Möller, C., Pijnenburg, Y. A. L., van der Flier, W. M., Versteeg, A., Tijms, B., de Munck, J. C., Hafkemeijer, A., Rombouts, S. A. R. B., van der Grond, J., van Swieten, J., et al. (2016) · Radiology · doi:10.1148/radiol.2015150220 · Cited by 103
Metadata
- Authors
- Greicius, M. D.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2002-06-01
- Volume
- 72
- Issue
- 6
- Pages
- 691-700
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2146134961
- Cited by
- 85
- References
- 24
- FWCI
- 2.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.